MedTrace Logo

Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major

NCT00103753 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2005-06-24

No results posted yet for this study

Summary

Thalassemia major is a genetic disorder affecting hemoglobin synthesis, rendering individuals dependent upon lifelong blood transfusions. Consequently, iron overload occurs and patients have shortened life expectancy with the most common cause of death being heart failure. This trial tests whether the combination of traditional therapy (deferoxamine) with a newer drug (deferiprone) will prove more effective in removing cardiac iron than deferoxamine alone.

Conditions

Interventions

DRUG

deferiprone

Sponsors & Collaborators

  • CORDA, The Heart Charity

    collaborator OTHER

  • The Cooley's Anemia Foundation,

    collaborator OTHER

  • Apotex Inc.

    collaborator INDUSTRY

  • The UK Thalassemia Society

    collaborator OTHER

  • Royal Brompton & Harefield NHS Foundation Trust

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Completion
2005-06-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00103753 on ClinicalTrials.gov